Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 388

1.

Erratum: A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.

Rivas MA, Graham D, Sulem P, Stevens C, Desch AN, Goyette P, Gudbjartsson D, Jonsdottir I, Thorsteinsdottir U, Degenhardt F, Mucha S, Kurki MI, Li D, D'Amato M, Annese V, Vermeire S, Weersma RK, Halfvarson J, Paavola-Sakki P, Lappalainen M, Lek M, Cummings B, Tukiainen T, Haritunians T, Halme L, Koskinen LL, Ananthakrishnan AN, Luo Y, Heap GA, Visschedijk MC; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, MacArthur DG, Neale BM, Ahmad T, Anderson CA, Brant SR, Duerr RH, Silverberg MS, Cho JH, Palotie A, Saavalainen P, Kontula K, Färkkilä M, McGovern DP, Franke A, Stefansson K, Rioux JD, Xavier RJ, Daly MJ.

Nat Commun. 2016 Sep 13;7:12869. doi: 10.1038/ncomms12869. No abstract available.

2.

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.

Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD.

Springerplus. 2016 Aug 19;5(1):1365. doi: 10.1186/s40064-016-2920-z. eCollection 2016.

3.

Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis.

Tenca A, Färkkilä M, Arola J, Jaakkola T, Penagini R, Kolho KL.

United European Gastroenterol J. 2016 Aug;4(4):562-9. doi: 10.1177/2050640615616012. Epub 2015 Oct 30.

4.

A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.

Rivas MA, Graham D, Sulem P, Stevens C, Desch AN, Goyette P, Gudbjartsson D, Jonsdottir I, Thorsteinsdottir U, Degenhardt F, Mucha S, Kurki MI, Li D, D'Amato M, Annese V, Vermeire S, Weersma RK, Halfvarson J, Paavola-Sakki P, Lappalainen M, Lek M, Cummings B, Tukiainen T, Haritunians T, Halme L, Koskinen LL, Ananthakrishnan AN, Luo Y, Heap GA, Visschedijk MC; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, MacArthur DG, Neale BM, Ahmad T, Anderson CA, Brant SR, Duerr RH, Silverberg MS, Cho JH, Palotie A, Saavalainen P, Kontula K, Färkkilä M, McGovern DP, Franke A, Stefansson K, Rioux JD, Xavier RJ, Daly MJ, Barrett J, de Lane K, Edwards C, Hart A, Hawkey C, Jostins L, Kennedy N, Lamb C, Lee J, Lees C, Mansfield J, Mathew C, Mowatt C, Newman B, Nimmo E, Parkes M, Pollard M, Prescott N, Randall J, Rice D, Satsangi J, Simmons A, Tremelling M, Uhlig H, Wilson D, Abraham C, Achkar JP, Bitton A, Boucher G, Croitoru K, Fleshner P, Glas J, Kugathasan S, Limbergen JV, Milgrom R, Proctor D, Regueiro M, Schumm PL, Sharma Y, Stempak JM, Targan SR, Wang MH.

Nat Commun. 2016 Aug 9;7:12342. doi: 10.1038/ncomms12342.

5.

[Risk factors and possibilities of prevention of bowel cancer].

Mecklin JP, Malila N, Kääriginen H, Pajari AM, Färkkilä M.

Duodecim. 2016;132(12):1145-52. Review. Finnish.

PMID:
27483630
6.

Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.

Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M.

Eur J Clin Invest. 2016 Jul 20. doi: 10.1111/eci.12660. [Epub ahead of print]

PMID:
27438629
7.

Letter: risk factor and mortality of peptic ulcer disease - authors' reply.

Malmi H, Kautiainen H, Virta LJ, Färkkilä MA.

Aliment Pharmacol Ther. 2016 Aug;44(4):425. doi: 10.1111/apt.13720. No abstract available.

PMID:
27413000
8.

Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine.

Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, Farh KH, Cuenca-Leon E, Muona M, Furlotte NA, Kurth T, Ingason A, McMahon G, Ligthart L, Terwindt GM, Kallela M, Freilinger TM, Ran C, Gordon SG, Stam AH, Steinberg S, Borck G, Koiranen M, Quaye L, Adams HH, Lehtimäki T, Sarin AP, Wedenoja J, Hinds DA, Buring JE, Schürks M, Ridker PM, Hrafnsdottir MG, Stefansson H, Ring SM, Hottenga JJ, Penninx BW, Färkkilä M, Artto V, Kaunisto M, Vepsäläinen S, Malik R, Heath AC, Madden PA, Martin NG, Montgomery GW, Kurki MI, Kals M, Mägi R, Pärn K, Hämäläinen E, Huang H, Byrnes AE, Franke L, Huang J, Stergiakouli E, Lee PH, Sandor C, Webber C, Cader Z, Muller-Myhsok B, Schreiber S, Meitinger T, Eriksson JG, Salomaa V, Heikkilä K, Loehrer E, Uitterlinden AG, Hofman A, van Duijn CM, Cherkas L, Pedersen LM, Stubhaug A, Nielsen CS, Männikkö M, Mihailov E, Milani L, Göbel H, Esserlind AL, Christensen AF, Hansen TF, Werge T; International Headache Genetics Consortium, Kaprio J, Aromaa AJ, Raitakari O, Ikram MA, Spector T, Järvelin MR, Metspalu A, Kubisch C, Strachan DP, Ferrari MD, Belin AC, Dichgans M, Wessman M, van den Maagdenberg AM, Zwart JA, Boomsma DI, Smith GD, Stefansson K, Eriksson N, Daly MJ, Neale BM, Olesen J, Chasman DI, Nyholt DR, Palotie A.

Nat Genet. 2016 Aug;48(8):856-66. doi: 10.1038/ng.3598. Epub 2016 Jun 20.

PMID:
27322543
9.

Increased short- and long-term mortality in 8146 hospitalised peptic ulcer patients.

Malmi H, Kautiainen H, Virta LJ, Färkkilä MA.

Aliment Pharmacol Ther. 2016 Aug;44(3):234-45. doi: 10.1111/apt.13682. Epub 2016 May 30.

PMID:
27240732
10.

Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study.

Sahlman P, Nissinen M, Pukkala E, Färkkilä M.

Scand J Gastroenterol. 2016 Aug;51(8):961-6. doi: 10.3109/00365521.2016.1157889. Epub 2016 May 16.

PMID:
27181618
11.

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.

Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkilä M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Rauning Buhl M, Stenmark S, Lagging M.

PLoS One. 2016 May 11;11(5):e0155142. doi: 10.1371/journal.pone.0155142. eCollection 2016.

12.

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.

Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K; RECYCLINE Study Investigators.

Eur J Neurol. 2016 May;23(5):861-70. doi: 10.1111/ene.12953. Epub 2016 Feb 5.

PMID:
26848561
13.

Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia.

Boyd S, Tenca A, Jokelainen K, Mustonen H, Krogerus L, Arola J, Färkkilä MA.

Endoscopy. 2016 May;48(5):432-9. doi: 10.1055/s-0041-110792. Epub 2016 Jan 25.

PMID:
26808393
14.

Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996-2013.

Sahlman P, Nissinen M, Pukkala E, Färkkilä M.

Int J Cancer. 2016 Jun 1;138(11):2616-21. doi: 10.1002/ijc.29995. Epub 2016 Jan 30.

PMID:
26756434
15.

Infliximab-induced skin manifestations in patients with inflammatory bowel disease.

Hellström AE, Färkkilä M, Kolho KL.

Scand J Gastroenterol. 2016;51(5):563-71. doi: 10.3109/00365521.2015.1125524. Epub 2016 Jan 5.

PMID:
26728295
16.

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.

Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives.

Gastroenterology. 2016 Feb;150(2):380-8.e4. doi: 10.1053/j.gastro.2015.10.050. Epub 2015 Nov 26.

PMID:
26632520
17.

[Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis].

Elovaara I, Soilu-Hänninen M, Kuusisto H, Martola J, Tienari P, Färkkilä M, Remes AM.

Duodecim. 2015;131(17):1571-80. Review. Finnish.

PMID:
26548104
18.

Environmental Risk Factors of Pediatric-Onset Primary Sclerosing Cholangitis and Autoimmune Hepatitis.

Tenca A, Färkkilä M, Jalanko H, Vapalahti K, Arola J, Jaakkola T, Penagini R, Vapalahti O, Kolho KL.

J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):437-42. doi: 10.1097/MPG.0000000000000995.

PMID:
26465796
19.

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.

Waldenström J, Färkkilä M, Rembeck K, Norkrans G, Langeland N, Mørch K, Pedersen C, Rauning Buhl M, Nieminen U, Nuutinen H, Alsiö Å, Holmström L, Jungnelius R, Lund K, Rubensson A, Torell E, Westin J, Lagging M.

Scand J Gastroenterol. 2016 Mar;51(3):337-43. doi: 10.3109/00365521.2015.1087588. Epub 2015 Sep 29.

20.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
Items per page

Supplemental Content

Loading ...
Write to the Help Desk